These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 29067667)

  • 1. Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes Is a Biomarker for Disease Progression in Duchenne Muscular Dystrophy.
    Savino W; Pinto-Mariz F; Mouly V
    Methods Mol Biol; 2018; 1687():219-227. PubMed ID: 29067667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy.
    Pinto-Mariz F; Rodrigues Carvalho L; Prufer De Queiroz Campos Araujo A; De Mello W; Gonçalves Ribeiro M; Cunha Mdo C; Cabello PH; Riederer I; Negroni E; Desguerre I; Veras M; Yada E; Allenbach Y; Benveniste O; Voit T; Mouly V; Silva-Barbosa SD; Butler-Browne G; Savino W
    Skelet Muscle; 2015; 5():45. PubMed ID: 26664665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
    Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential integrin expression by T lymphocytes: potential role in DMD muscle damage.
    Pinto-Mariz F; Carvalho LR; de Mello W; Araújo Ade Q; Ribeiro MG; Cunha Mdo C; Voit T; Butler-Browne G; Silva-Barbosa SD; Savino W
    J Neuroimmunol; 2010 Jun; 223(1-2):128-30. PubMed ID: 20382434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies.
    Banks GB; Chamberlain JS
    Curr Top Dev Biol; 2008; 84():431-53. PubMed ID: 19186250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the role of skewed X-chromosome inactivation in developing muscle symptoms in carriers of Duchenne muscular dystrophy.
    Viggiano E; Ergoli M; Picillo E; Politano L
    Hum Genet; 2016 Jul; 135(7):685-98. PubMed ID: 27098336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy.
    Beekman C; Janson AA; Baghat A; van Deutekom JC; Datson NA
    PLoS One; 2018; 13(4):e0195850. PubMed ID: 29641567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphism in muscle biopsies of Duchenne and Becker muscular dystrophy patients.
    Anand A; Prabhakar S; Kaul D
    Neurol India; 1999 Sep; 47(3):218-23. PubMed ID: 10514583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of MicroRNA in the Pathogenesis of Duchenne Muscular Dystrophy.
    Kiełbowski K; Bakinowska E; Procyk G; Ziętara M; Pawlik A
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duchenne muscular dystrophy: a clinical, histopathological and genetic study at a neurology tertiary care center in Southern India.
    Swaminathan B; Shubha GN; Shubha D; Murthy AR; Kiran Kumar HB; Shylashree S; Gayathri N; Jamuna R; Jain S; Purushottam M; Nalini A
    Neurol India; 2009; 57(6):734-8. PubMed ID: 20139501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the Inflammatory Response in Dystrophic Muscle Using Flow Cytometry.
    Kastenschmidt JM; Avetyan I; Villalta SA
    Methods Mol Biol; 2018; 1687():43-56. PubMed ID: 29067655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Genotype-phenotype discordance in a Duchenne muscular dystrophy patient due to a novel mutation: insights into the shock absorber function of dystrophin].
    López-Hernández LB; van Heusden D; Soriano-Ursúa MA; Figuera-Villanueva L; Vázquez-Cárdenas NA; Canto P; Gómez-Díaz B; Coral-Vázquez RM
    Rev Neurol; 2011 Jun; 52(12):720-4. PubMed ID: 21594857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle.
    Haslett JN; Sanoudou D; Kho AT; Bennett RR; Greenberg SA; Kohane IS; Beggs AH; Kunkel LM
    Proc Natl Acad Sci U S A; 2002 Nov; 99(23):15000-5. PubMed ID: 12415109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA Profiling for Early Detection and Treatment of Duchenne Muscular Dystrophy.
    Hrach HC; Mangone M
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibronectin is a serum biomarker for Duchenne muscular dystrophy.
    Cynthia Martin F; Hiller M; Spitali P; Oonk S; Dalebout H; Palmblad M; Chaouch A; Guglieri M; Straub V; Lochmüller H; Niks EH; Verschuuren JJ; Aartsma-Rus A; Deelder AM; van der Burgt YE; 't Hoen PA
    Proteomics Clin Appl; 2014 Apr; 8(3-4):269-78. PubMed ID: 24458521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker Potential of Extracellular miRNAs in Duchenne Muscular Dystrophy.
    Coenen-Stass AML; Wood MJA; Roberts TC
    Trends Mol Med; 2017 Nov; 23(11):989-1001. PubMed ID: 28988850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice.
    Woodcock IR; Tachas G; Desem N; Houweling PJ; Kean M; Emmanuel J; Kennedy R; Carroll K; de Valle K; Adams J; Lamandé SR; Coles C; Tiong C; Burton M; Villano D; Button P; Hogrel JY; Catling-Seyffer S; Ryan MM; Delatycki MB; Yiu EM
    PLoS One; 2024; 19(1):e0294847. PubMed ID: 38271438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy.
    Ito M; Ehara Y; Li J; Inada K; Ohno K
    Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy.
    Porter JD; Merriam AP; Leahy P; Gong B; Feuerman J; Cheng G; Khanna S
    Hum Mol Genet; 2004 Feb; 13(3):257-69. PubMed ID: 14681298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.